Tatva Chintan Pharma IPO

Tatva Chintan Pharma IPO

Spread the love

Tatva Chintan Pharma IPO will open for subscription from 16 July 2021. the company aims for an issue size of ₹500 Crore through this IPO.

Also read: IPO List 2021: a complete list of IPOs in 2021

Tatva Chintan Pharma Chem Limited

Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a chemical manufacturing company that manufactures structure-directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals. It is among the largest manufacturer of SDAs for zeolites in India.

The company serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others. Its products are not only sold in India but also export to 25+ countries all over the world such as the USA, Germany, South Africa, China, and the UK. In FY 2020, total export contributed to 76% of total revenue from operations.

Merck, Bayer AG, Ipox Chemicals, Laurus labs, Navin Fluorine International Limited, Atul Limited, Otsuka Chemicals, SRF Limited, Hawks Chemical Company, Firmenich Aromatics Prod Pvt Ltd, and Divi’s laboratories are a few of customers of the company. Currently, it has two manufacturing facilities at Ankleshwar and Dahej in Gujarat.

Objects of the Issue

  • Funding capital expenditures requirements for expansion of Dahej manufacturing facility.
  • To meet general corporate purposes.
  • Funding capital expenditures requirements to upgrade R&D facilities in Vadodara.

Competitive strengths

  • Leading manufacturer of structure-directing agents and phase transfer catalysts.
  • Diversified product portfolio.
  • Global market presence with a customer base across industries.
  • Strategically located manufacturing facility in Gujarat with close proximity to Hazira Port.
  • Experienced promoters and managers team.
  • Strong financial performance track record.

Basic details about the company

Full nameTatva Chintan Pharma Chem Ltd
SectorChemicals
IndustryChemicals
Company Websitewww.tatvachintan.com

Dates to remember

IPO Open16 July 2021
IPO Close20 July 2021
Basis of Allotment26 July 2021
Refunds date27 July 2021
Credit to Demat Account28 July 2021
 Listing Date29 July 2021

IPO details

Issue typeBook Building
IPO issue size₹500 Crore
Fresh Issue₹225 Cr
Offer for sale₹275 Cr
Face value₹10 Per Equity Share
Price band₹1073 to ₹1083 per equity share
Retail Allocation35%
Lot size13 Shares
Minimum application1 Lot13 Shares
Maximum application13 Lots-182
Minimum application amount₹14,079
Maximum application amount₹197,106
Listing ExchangeBSE & NSE

Company Financials

ParticularsFor the year/period ended (₹ in million)
31-Mar-2131-Mar-2031-Mar-19
Total Assets3,148.032,489.381,875.08
Total Revenue3,062.922,646.222,068.01
Profit After Tax522.62377.89205.43

Valuation of Tatva Chintan Pharma (as of FY2020)

Earnings Per Share (EPS)₹26.02
Price/Earnings (PE ratio)41.24 – 41.62
Return on Net Worth (RONW)31.49%
Net Asset Value (NAV)₹82.62 per share

Company Promoters

  • Ajaykumar Mansukhlal Patel
  • Chintan Nitinkumar Shah
  • Snehkar Rasiklal Somani

Lead Managers

  • ICICI Securities Limited
  • JM Financial Consultants Private Limited

Registrar of Tatva Chintan Pharma IPO

Link Intime India Private Limited C-101, 1st Floor,
247 Park Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: tatva.ipo@linkintime.co.in
Website: http://www.linkintime.co.in

Tatva Chintan Pharma Contact Details

Tatva Chintan Pharma Chem Limited
Plot No. 353, Makarpura GIDC,
Vadodara, Gujarat – 390 010
Phone: +91 75748 48533
Email: cs@tatvachintan.com
Website: www.tatvachintan.com

Tatva Chintan Pharma IPO Allotment Status

Tatva Chintan Pharma IPO allotment status will be available on Link Intime’s website.

Click on this link to get allotment status.

Final thoughts

Tatva Chintan Pharma IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make a wise decision.

Happy Investing


Spread the love

Leave a Comment

Your email address will not be published. Required fields are marked *